Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial

RK Avery, S Alain, BD Alexander… - Clinical Infectious …, 2022 - academic.oup.com
Background Therapies for refractory cytomegalovirus infections (with or without resistance
[R/R]) in transplant recipients are limited by toxicities. Maribavir has multimodal anti …
被引用次数：154 相关文章
[HTML] nih.gov

[HTML][HTML] Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial

RK Avery, S Alain, BD Alexander… - … Diseases: An Official …, 2022 - ncbi.nlm.nih.gov
Background Therapies for refractory cytomegalovirus infections (with or without resistance
[R/R]) in transplant recipients are limited by toxicities. Maribavir has multimodal anti …
[PDF] archive.org

[PDF][PDF] Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results from a Phase 3 Randomized Clinical Trial

RK Avery, S Alain, BD Alexander, EA Blumberg… - 2021 - scholar.archive.org
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant:
Results from a Phase 3 Randomize Page 1 © The Author(s) 2021. Published by Oxford …

Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial

RK Avery, S Alain, BD Alexander… - Clinical Infectious …, 2022 - pure.johnshopkins.edu
Background: Therapies for refractory cytomegalovirus infections (with or without resistance
[R/R]) in transplant recipients are limited by toxicities. Maribavir has multimodal anti …
[HTML] duke.edu

[HTML][HTML] Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial.

RK Avery, S Alain, BD Alexander, EA Blumberg… - 2022 - dukespace.lib.duke.edu
Background Therapies for refractory cytomegalovirus infections (with or without resistance
[R/R]) in transplant recipients are limited by toxicities. Maribavir has multimodal anti …

Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial

RK Avery, S Alain, BD Alexander… - Clinical …, 2022 - mdanderson.elsevierpure.com
Background: Therapies for refractory cytomegalovirus infections (with or without resistance
[R/R]) in transplant recipients are limited by toxicities. Maribavir has multimodal anti …

Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial.

RK Avery, S Alain, BD Alexander… - Clinical Infectious …, 2022 - search.ebscohost.com
Background Therapies for refractory cytomegalovirus infections (with or without resistance
[R/R]) in transplant recipients are limited by toxicities. Maribavir has multimodal anti …

Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial

RK Avery, S Alain, BD Alexander… - Clinical Infectious …, 2022 - lirias.kuleuven.be
BACKGROUND: Therapies for refractory cytomegalovirus infections (with or without
resistance [R/R]) in transplant recipients are limited by toxicities. Maribavir has multimodal …
[HTML] oup.com

[HTML][HTML] Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial

RK Avery, S Alain, BD Alexander… - Clinical Infectious …, 2022 - academic.oup.com
Background Therapies for refractory cytomegalovirus infections (with or without resistance
[R/R]) in transplant recipients are limited by toxicities. Maribavir has multimodal anti …

Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial

RK Avery, S Alain, BD Alexander… - Clinical Infectious …, 2022 - experts.nebraska.edu
Background: Therapies for refractory cytomegalovirus infections (with or without resistance
[R/R]) in transplant recipients are limited by toxicities. Maribavir has multimodal anti …